Actively Recruiting
Modified Second Haploidentical Stem Cell Transplantation to Treat Graft Failure After First Transplant
Led by Peking University People's Hospital · Updated on 2024-11-29
12
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What this Trial Is About
Graft failure is a serious complication that can occur after an allogeneic stem cell transplantation, often requiring a second transplantation. Researchers are evaluating a modified regimen designed to improve blood cell recovery after a second haploidentical stem cell transplantation for patients experiencing graft failure. This prospective, single-arm study aims to assess the safety and effectiveness of this new approach. The study involves a second allogeneic stem cell transplantation with a modified conditioning regimen including fludarabine, cyclophosphamide, and rabbit antithymocyte globulin. Additional treatments include graft-versus-host disease GVHD prevention with cyclosporine A, mycophenolate mofetil, and anti-CD25 monoclonal antibody. When possible, a different donor will be selected for the second transplant. Participants will be monitored for neutrophil engraftment by 28 days and platelet engraftment by 100 days after the second transplantation. The study will also follow transplant-related mortality, GVHD, overall survival, leukemia-free survival, and relapse incidence for about one year. Safety, effectiveness, and blood recovery will be carefully evaluated throughout the study period.
CONDITIONS
Brief Title
Modified Second Haplo-transplantation for Graft Failure
Research Team
Y
Yu-qian Sun, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
